Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: A study in adult patients with acquired anemias

Blood

Volumn 101, Issue 1, 2003, Pages 91-96

  Jensen, Peter D ^a   Jensen, Finn T ^a   Christensen, Thorkil ^a   Nielsen, Johan L ^a   Ellegaard, Joergen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; DEFEROXAMINE; FERRITIN; HEPATITIS C ANTIBODY; IRON; TRANSFERRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BOLUS INJECTION; CLINICAL ARTICLE; DRUG INFUSION; FEMALE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER CELL DAMAGE; MALE; PRIORITY JOURNAL; THALASSEMIA; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0037222940     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1704     Document Type: Article

References (35)

1. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-768.
2. Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox Sang. 2000;79:129-137.
3. De Virgiliis S, Cornacchia G, Sanna G, et al. Chronic liver disease in transfusion-dependent thalassemia: Liver iron quantitation and distribution. Acta Haematol. 1981;65:32-39.
4. Hoffbrand AV, Gorman A, Laulicht M, et al. Improvement in iron status and liver function in patients with transfusional iron overload with longterm subcutaneous desferrioxamine. Lancet. 1979;1:947-949.
5. Aldouri MA, Wonke B, Hoffbrand AV, et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol. 1987;40:1353-1359.
6. Lund BV, Korsgaard N, Peterslund NA. Hepatitis C antibody in hematological patients who underwent multiple transfusions. Ugeskr Laeger. 1991;153:3084-3086.
7. Azar N, Valla D, Abdel-Samad I, et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation. 1996;62:56-61.
8. McKay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17:63-66.
9. Strasser SI, Kowdley KV, Sale GE, McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant. 1998;22:167-173.
10. Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia; manifestations and therapy. Am J Med Sci. 2000;319:73-78.
11. Tomas JF, Pinilla I, Garcia-Buey ML, et al. Longterm liver dysfunction after allogeneic bone marrow transplantation: Clinical features and course in 61 patients. Bone Marrow Transplant. 2000;26:649-655.
12. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304:319-324.
13. Poli G. Pathogenesis of liver fibrosis: Role of oxidative stress. Mol Aspects Med. 2000;21:49-98.
14. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6:24-29.
15. Jensen PD, Jensen FT, Christensen T, et al. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. Magma. 2001;12:153-166.
16. Jensen PD, Olsen N, Bagger JP, et al. Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload. Eur J Haematol. 1997;59:221-230.
17. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br J Haematol. 1995;89:880-889.
18. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 1997;349:321-323.
19. Zettner A, Mansbach L. Application of atomic absorption spectrophotometry in the determination of iron in urine. Am J Clin Pathol. 1965;44:517-519.
20. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol. 1994;87:171-184.
21. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol. 1998;101:399-406.
22. Prati D, Zanella A, Farma E, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood. 1998;92:3460-3464.
23. Boyd JW. The intracellular distribution, latency and electrophoretic mobility of L-glutamic oxaloacetic transaminase. Biochem J. 1970;81:433-438.
24. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol. 1998;28(suppl 1):8-13.
25. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281-289.
26. Worwood M, Cragg SJ, Jacobs A, et al. Binding of serum ferritin to concanavalin A: Patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol. 1980;46:409-416.
27. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol. 1990;43:638-640.
28. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 1977;50:433-439.
29. Crichton RR, Ward RJ. Iron species in iron homeostasis and toxicity. Analyst. 1995;120:693-697.
30. Breuer W, Epsztein S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem. 1995;270:24209-24215.
31. Breuer W, Epsztejn S, ZI C. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 1997;382:304-308.
32. Inoue M. Protective mechanisms against reactive oxygen species. In: Arias IM, Bojer JL, Fausto N, Jacoby WB, Schachter D, Shafritz DA, eds. The Liver, Biology and Pathobiology. New York, NY: Raven Press; 1994:443-459.
33. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
34. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-977.
35. Olivieri NF, Brittenham GM. Iron-chelation therapy and the treatment of thalassemia. Blood. 1997;89:739-781.